← boardnext 2026-08
EYPT
EyePoint Pharmaceuticals, Inc.distress 6/10 · elevated risk$12.36-2%today-34% from 52w high
Lead: wet age-related macular degeneration · est. market ~$12B (approx, global)
Revenue
pre-revenue
Liquidity
$223M
Runway
0.8 yrs
Shares 1y
+22%
Price & events
-24.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.4%
1D
-5.3%
1W
-14.1%
1M
-10.7%
3M
-18.6%
6M
+15.5%
1Y
+29.1%
2Y
+49.9%
5Y
+37.1%
All
Overview
- Market Cap
- $1.04B
- Volume
- 57.22K
- 52 Week Range
- $9.71 – $18.85
- Total Shares
- 83.84M
- Float Shares
- 70.47M
- Short %
- 19.00%
- % Held by Insiders
- 3.67%
- % Held by Institutions
- 111.93%
- RVOL
- 0.04x
- Beta
- 1.74
Pipeline stages · 1 programs
EYP-1901, Aflibercept (2.0 mg)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | EYP-1901, Aflibercept (2.0 mg) | Wet Age Related Macular Degeneration, wAMD | — | active not recruiting |
| 2026-10 Estimated 50% readout ~2026-12-15 | Phase 3 | EYP-1901, Aflibercept (2.0 mg) | Wet Age Related Macular Degeneration, wAMD | — | active not recruiting |
| 2027-10 Estimated 50% readout ~2027-12-15 | Phase 3 | EYP-1901, Aflibercept (2.0 mg) | Diabetic Macular Edema, DME, Diabetic Macular Edema (DME) | — | recruiting |
| 2027-10 Estimated 50% readout ~2027-12-15 | Phase 3 | EYP-1901, Aflibercept (2.0 mg) | Diabetic Macular Edema, DME, Diabetic Macular Edema (DME) | — | recruiting |
Catalyst news & presentations · 12
- second half of 2027Guided 55%readoutPhase 3DURAVYU · Topline data for DURAVYU in DME anticipated in 2H 2027.SEC 8-K
- second half of 2026Guided 55%readoutPhase 3DURAVYU · Topline data for LUCIA expected in second half of 2026.SEC 8-K
- 3Q 2026Guided 70%enrollment completesecondaryPhase 3DURAVYU · CAPRI trial full enrollmentSEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026readoutPhase 3DURAVYU · Topline 56-week data for LUGANO expected mid-2026.SEC 8-K
- mid-2026readoutPhase 3DURAVYU · Topline 56-week data for LUGANO trialSEC 8-K
- first quarter of 2026trial initiationsecondaryPhase 3DURAVYU · First patient dosing in pivotal Phase 3 trials (COMO and CAPRI)SEC 8-K
- 2H 2025enrollment completesecondaryPhase 3DURAVYU · Full enrollment for LUGANO/LUCIA Phase 3 trialsSEC 8-K
- 3Q 2025enrollment completesecondaryPhase 3DURAVYU · Enrollment completion expected for LUCIA trial in 3Q 2025.SEC 8-K
- May 2025conferencedata presentationsecondaryDURAVYU · 24-week topline results from Phase 2 VERONA presented at Retina World CongressSEC 8-K
- May 27, 2025enrollment completesecondaryPhase 3DURAVYU · Completed enrollment of over 400 patients in Phase 3 LUGANO trial.SEC 8-K
- 2024trial initiationsecondaryPhase 3DURAVYU · First patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU in wet AMD.SEC 8-K
Approved drugs (1)
- DEXYCU KITDEXAMETHASONE2018 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $41 (+228% upside) · 14 analysts
- 2026-07-16StifelBuy
- 2026-07-01Chardan CapitalBuy
- 2026-06-24GuggenheimBuy
- 2026-05-07RBC CapitalOutperform
- 2026-03-09CitigroupBuy
- 2026-03-05HC Wainwright & Co.Buy
Competitors — wet age-related macular degeneration
Recent news
- 2026-07-22EYPT (NASDAQ: EYPT) plans sale of 1,235 common shares from options - Stock Titan
- 2026-07-22EYPT (NASDAQ: EYPT) affiliate plans sale of 1,235 common shares via Form 144 - Stock Titan
- 2026-07-22Form 144 EyePoint For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-21Form 144 EyePoint For: 21 July By Investing.com - Investing.com Canada
- 2026-07-21EYPT (NASDAQ: EYPT) plans brokered sale of 421,235 shares valued at $5.5M - Stock Titan
- 2026-07-18EyePoint Pharmaceuticals Agrees to Pay $4.6 Million to Settle False Claims Act Allegations - Markets Herald
- 2026-07-18EyePoint, Inc. Settles DOJ False Claims Act Case and Implements Comprehensive Compliance Program - Minichart
- 2026-07-18Price-Driven Insight from (EYPT) for Rule-Based Strategy - Stock Traders Daily
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.